PIK3CA and mantle cell lymphoma: For instance, the combination of TGR-1202, a PI3K delta inhibitor, with ibrutinib had an overall response rate of 67% with six out of nine patients achieving a partial response in a phase I/Ib multicenter trial for patients with relapsed/refractory MCL [52].